May 10, 2018 / 11:07 AM / 2 months ago

BRIEF-Sierra Oncology Reports Qtrly Loss Per Share $0.19

May 10 (Reuters) - Sierra Oncology Inc:

* SIERRA ONCOLOGY INC QTRLY LOSS PER SHARE $0.19

* SIERRA ONCOLOGY INC - SRA737 MONOTHERAPY PHASE 1/2 TRIAL EXPANDED TO ENROLL CCNE1-DRIVEN OVARIAN CANCER COHORT

* SIERRA ONCOLOGY INC - SRA737 LOW-DOSE GEMCITABINE COMBINATION PHASE 1/2 TRIAL ADVANCED INTO COHORT EXPANSION PHASE

* SIERRA ONCOLOGY INC - CASH AND CASH EQUIVALENTS TOTALED $133.8 MILLION AS OF MARCH 31, 2018

* SIERRA ONCOLOGY INC - $133.8 MILLION CASH EXPECTED TO FUND PROGRAMS THROUGH APPROXIMATELY MID-2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below